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A B S T R A C T
Esophageal cancers (EC) are highly aggressive tumors, commonly presented in a locally advanced stage with a
poor prognosis and survival. Up to 50% of the patients are eligible for treatment with curative intent and receive
the standard treatment with neoadjuvant chemoradiotherapy (nCRT) and surgery. Currently, pathologic
complete response to nCRT is 20–30%, with a partial or no response in about 50% and 20%, respectively. EC
recurrences occur frequently even after successful anti-cancer treatment, suggesting high aggressiveness with
increased metastatic potential. A tumor sub-population of so-called cancer stem cells (CSCs), is known to display
a high metastatic potential and resistance to conventional anti-cancer therapy, hereby being responsible for the
unbeneﬁcial clinical features. In this review, a concise overview will be given of the current literature on
esophageal CSCs and related metastases. Esophageal CSC markers will be discussed followed by the pathways
that initiate and sustain these cells. In addition, the cellular processes, epithelial-mesenchymal transition (EMT),
hypoxia and autophagy, known to contribute to cancer stemness and metastasis will be explained. Finally,
potential options for treatment also related to cancer genome atlas (TCGA) data on EC will be discussed.
1. Introduction
Esophageal cancer (EC) is currently the 8th most common malig-
nancy worldwide and the 6th leading cause of cancer related death,
accounting for more than 490 000 new cases and 400 000 deaths in
2014 (world cancer report 2014). The 5-year survival of this highly
aggressive tumor is approximately 20% (www.cancer.org). At diagno-
sis, patients often present with locally advanced tumors, including
lymph node involvement in more than 75%. Usually symptoms occur
when the tumor has inﬁltrated over half of the circumference of the
esophagus or has spread by direct local growth in the adventitial
tissues, via lymph vessels to surrounding nodes and distantly through
hematogenous dissemination. Distant metastases are frequently ob-
served in the liver, lungs, bones, adrenal glands, kidney and brain [1].
There are two typical esophageal cancers, esophageal squamous cell
carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC,
predominantly present in the Eastern and Central Asian world, derives
from dysplastic squamous cell epithelium that usually occurs in the
upper two-third of the esophagus. EAC mainly develops in the distal
esophagus, where ongoing gastroesophageal reﬂux esophagitis poten-
tially transforms squamous epithelium into columnar intestinal epithe-
lium that further evolves through low and high grade dysplasia into
EAC [1,2]. Alcohol and tobacco are the most important risk factors of
ESCC whereas EAC is associated with obesity, smoking and chronic
gastroesophageal reﬂux disease (GERD) with premalignant Barrett’s
esophagus [3,4]. Nodal metastases occur frequently in the mid and
upper mediastinum in ESCC and abdominal metastases in EAC [1]. The
treatment of choice for locally advanced resectable tumors, both ESCC
and EAC, is neoadjuvant chemoradiation (nCRT) followed by radical
surgery [5]. Regretfully, around 20% of the tumors will not respond at
all, more than 50% do not respond adequately, and even after
pathologic complete response early and distant recurrences occur in
most patients [6]. Therefore, it is necessary to investigate the sub-
population of cells with increased treatment resistance and metastatic
potential, the so-called cancer stem cells (CSCs) [7].
CSCs were ﬁrst proposed by Virchow and Conheim; a subpopulation
of cancer cells resembles the same traits as embryonic cells such as the
ability to proliferate, and cancer is derived from the activation of
dormant cells of the same tissue [8]. One of the ﬁrst experiments
conﬁrming the existence of CSCs, showed indeed that only a limited
percentage of transplanted primary tumor cells could initiate a
secondary tumor [9]. Subsequent research used FACS and cell surface
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markers to further characterize CSCs and investigate mechanisms
involved in the regulation of cancer stemness [10,11]. CSCs are, in
contrast to non-CSCs, thought to be dormant or quiescent [12,13] and
therefore therapy resistant but when re-entering the cell cycle are able
to form recurrences or metastases [11,13,14]. In vitro cancer sphere
forming potential and in vivo tumor initiating potential are often used
as read-outs for cancer stemness [15–17]. It is believed that CSCs
represent a small percentage of all EC cells with the majority part
consist of more diﬀerentiated cells [18], albeit this has recently been
challenged by studies showing plasticity of diﬀerentiated tumor cells
[19,20].
This review will focus on EC CSCs as a target for eliminating
resistant and highly metastatic cell populations and the role of tumor
microenvironment in facilitating this process.
2. Markers to identify esophageal CSCs
Although the use of markers to select CSC enriched populations is
disputed due to the lack of universal markers owing to tumor hetero-
geneity, it tremendously contributed to current knowledge, including
that of EC [20–22] (Fig. 1).
CD44, a lymphocyte homing receptor that has a role in adhesion,
motility, proliferation and cell survival [23] has extensively been
studied both as a single and combined marker for CSCs. Interestingly,
several CD44 variants were suggested to be a prognostic marker for
adenocarcinoma of Barrett's esophagus [24] and ESCC [25]. Li et. al.
[26] ﬁrst suggested tumor stem-like cells to express CD44, being
enriched in culture and highly expressed after irradiation. Next, Zhao
et al. [27] showed increased colony formation, drug resistance and
ESCC tumor initiation of CD44 cells. Regretfully, CD44 is being
expressed by the majority of ESCCs in KYSE30 cells [28]. Combining
CD44 with other markers greatly enhances its discriminative properties.
As such, we [17] identiﬁed a CD44+/CD24− subpopulation with CSC-
like characteristics in esophageal cell lines OE33 (EAC), OE21 (ESCC),
and in EC tumor biopsies. CD24, a heat-stable cell surface antigen, has a
role in cell–matrix and cell–cell interactions [17,29]. CD44+/CD24−
cells had higher sphere forming potential, were more resistant to
irradiation, formed tumors more aggressively, resided in hypoxic niches
and the proportion of CD44+/CD24− cells correlated with the tumor
growth rate [17]. Furthermore, CD44+/CD24− were present in half of
the pretreatment biopsies of patients with residual EAC but not at all in
biopsies of patients with complete pathologic response after nCRT.
These results suggest that CD44+/CD24− cells have CSC-like features
and may be a target for therapy [17]. Based only on in vitro data CD44
in combination with aldehyde dehydrogenase 1 (ALDH1) was suggested
to identify EC stem-like cells [30,32]. Moreover, ALDH1 expression in
ESCCs was correlated with poor histological diﬀerentiation, lymph
node metastasis and pathologic TNM classiﬁcation [31–33], Even as a
single marker, ALDH1 seems to be enriched in ESCC cell line derived
tumor spheres and solely ALDH1high cells formed lung metastasis
[34–36], had high EMT potential, were more invasive, showed in-
creased metastic potential and were related to poor patient outcome
[37,38]. Therefore, ALDH1 seems to be a good candidate CSC marker
alone or in combination with CD44 [30]. Other combinations published
are CD44+/ICAM1+ [39] showing all major CSC-like phenotypes, and
CD44+/CD133+ that predict recurrence and prognosis of ESCC [40].
So compiling evidence indicates that CD44 in combination with other
markers may enrich for EC CSCs and is of at least some prognostic
value.
Another cell surface marker potentially identifying EC CSCs is
ABCG2, member of group G in the ATP-binding cassette (ABC)
transporter family [41]. In healthy tissue ABCG2 transporter functions
as a ﬁrst line defense mechanism against cytotoxic substances. In the
gastrointestinal tract, including the esophagus, ABCG2 is abundantly
Fig. 1. Overview of markers and pathways deﬁning esophageal CSC populations. Cell surface markers ABCG2, CD90, ITGA7 and CD44 are used as single markers while CD44 can be used
in combination with CD24 (CD44+/CD24−), CD133 (CD44+/CD133+), the intracellular marker ALDH1 (CD44+/ALDH1+) and ICAM1 (CD44+/ICAM1+) to identify CSCs. ALDH1 can
also be used as a single marker. CD133 can be used alone or in combination with ABCG2 and CXCR4. CD271 is another CSC marker. Other read-outs for cancer stemness are the
transcription factors Bmi-1, Nanog, Sox2 and Oct4. Hedgehog, Notch, WNT, PI3K/mTOR and Hippo pathways are implicated to regulate CSC populations leading to more proliferation,
invasiveness, therapy resistance and higher metastatic potential.
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expressed in the apical membrane of epithelial cells [42]. ABCG2 seems
to play a role in the proliferation tumor initiation [43,44] and
treatment resistance supported by reduced proliferation and migration
potential of ABCG2 knockdown cells [45]. Moreover, high ABCG2
expression in ESCC surgical material correlated with the pathological
tumor grading, TNM stages and with metastatic lymph nodes [43]. This
suggests that ABCG2 may be an excellent marker for EC CSCs.
Additionally, CD90 or Thy-1 marked cells of EC cell lines showed
increased sphere forming potential after serial passaging, eﬃciently
generated tumors, were chemotherapy resistant, had increased inva-
siveness, migration and lung metastatic potential, when compared to
CD90− cells, all indicative of CSC properties [46]. Integrin α7 (ITGA7),
critical for modulating cell-matrix interactions, positive cells, co-
express CD90 and has been suggested to mark EC CSCs with high
metastatic potential [47]. Moreover, ITGA7 overexpressing cells highly
expressed stemness genes (including Sox2, Oct4 and Nanog), showed
EMT features, had increased self-renewal and diﬀerentiation ability and
showed chemotherapy resistance. Knock down of ITGA7 reduced all
these characteristics indicating that ITGA7 could be a CSC marker and a
potential therapeutic target [47]. CD133 (prominin-1) has been identi-
ﬁed as an EC CSC marker [48] and was suggested to be of prognostic
value alone [49] or in combination with ABCG2 [48] or CXRC4 [50].
Finally, CD271 (p75 neurotropin receptor) expressing ESCC cells
possessed CSC characeristics like self-renewal and chemotherapy
resistance [51], metastatic capacity and could potential act as prog-
nostic marker for ESCC [52]. Less usable for characterization and more
general expressed in CSCs are Bmi-1, a downstream target of the
Hedgehog (HH) pathway and transcription factors Sox2, Oct-4 and
Nanog [53–57].
It seems clear that EC do contain cells with CSCs characteristic
which express markers that might be of prognostic or predictive value.
However, most data are derived from long established cell liness and
tumor tissue biopsies. Patient speciﬁc organoids such as those of human
metaplastic epithelia of Barrett's esophagus by Sato et al. [15] could
improve our insight in CSC of EC and related stem cells markers.
3. EC CSC signaling pathways
Wnt/β-catenin, Notch, Hedgehog and Hippo pathways play an
important role in proliferation, diﬀerentiation, and self-renewal of stem
cells, have been implicated in the regulation of EC CSCs and are
potential therapeutic targets (Fig. 1). WNT10A, an activator of the Wnt/
β-catenin pathway, was highly expressed in ESCC tissue which corre-
sponded with poor outcome. WNT10a expressing cells, showed enrich-
ment for CD44+/CD24− cells, increased self-renewal, invasive and
metastatic potential shown by sphere forming assays and Boyden
chamber assays, respectively [58]. Interestingly, Notch seems to co-
drive cancer stemness in EC as inhibition of the Notch pathway using γ-
secretase inhibitors downsized patient derived xenograft tumors,
whereas the level of Notch activity in EC biopsies may predict response
Fig. 2. The inﬂuence of the microenvironment and cellular processes in controlling the pool of esophageal CSCs. Autophagy, hypoxia, anti-cancer therapy and EMT, alone or in
combination, can lead to an enrichment of CSCs through aberrant activation of pathways facilitating the development of recurrences and metastases and increasing treatment resistance.
These processes can be targeted by diﬀerent drugs.
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to nCRT [59]. The Hedgehog pathway activation has been shown to be
associated with distant metastases, advanced tumor stage and higher
TNM stage [60–62]. Moreover, Hedgehog pathway activation may lead
to stimulation of EMT [11,61,63]. The PI3K/mTOR pathway integrates
a variety of signals and has been shown to interact with the Hedgehog
pathway [61,64,65]. Interestingly, mTOR inhibition enhances the
cytotoxic eﬀects of Hedgehog inhibition, suggesting a rational to
combine both mTOR inhibitor and Hedgehog inhibitor in future
therapy [64]. Recently, the Hippo pathway, that controls organ size
during development has been linked to cancer stemness EC
[11,12,64,66]. Expression of YAP1, Hippo coactivator, elevated SOX9
expression accompanied by the acquisition of CSC properties, whereas
knockdown of YAP1 or the use of YAP1 inhibitor Verteporﬁn abolished
CSC phenotypes [66]. Moreover, YAP1 mediates EGFR and confers
chemoresistance [67]. Interference with all these pathways using small
molecules could have therapeutic beneﬁts.
4. Epithelial-mesenchymal transition (EMT)
During cancer progression, a fraction of cancer cells may reactivate
EMT, originally necessary for the dissemination of diﬀerent primitive
cells to various parts of the embryo [68]. Cancer cells highjack this
mechanism to invade and develop metastasis [69] (Fig. 2). EMT is
characterized by loss of epithelial characteristics while transforming
into a multipolar, more motile and spindle-like mesenchymal pheno-
type [14,69–71]. Cancer cells that have undergone EMT are able to
cross the endothelium, enter the blood and the lymphatic system, to
regain the epithelial phenotype via a reversed process called mesench-
ymal-epithelial transition once the proper niche is reached and regrow
[70]. EC cells that have undergone EMT through tumor microenviron-
ment initiated activation of WNT, TGF-β and Hedgehog pathway
acquired hallmarks of CSCs such as increased invasiveness, metastases
and poor survival [56,63,72–78]. Radiation may induce EMT through
stimulation of TGF-β1 and HIF-1α signaling increasing CD44 expression
and upregulation of transcription factors such as Slug, Snail and Twist
or downregulation of PTEN [79,80].
5. Hypoxia
Hypoxia is a common characteristic in locally advanced solid
tumors. Poor tumor vasculature creates intratumoral hypoxic areas,
inducing neovascularization as a response to oxygen and nutrition
deprivation [81,82]. Hypoxia activates hypoxia-inducible factor (HIF)
1 & 2 that modulates metabolism, deregulates stem cell proliferation,
enhances aggressiveness and metastatic potential [81,82] (Fig. 2),
reduces radiosensitivity [83,84] induced EMT, and changes cell cycle
in EC [85,86]. Interestingly, inhibition of HIF1α suppresses tumor-
igenicity of ESCC both in vitro and in vivo [87]. Indeed, pretreatment
biopsy levels of hypoxia and HIF1α correlate with therapy resistance
and poor prognosis [77,88–90]. Although not shown in EC, hypoxia
targets Notch, Wnt/β-catenin, Hedgehog, PI3K/mTOR and unfolded
protein response (UPR) pathways to regulate EMT and CSC stemness
[91] and is activated by a number of oncogenes or loss of tumor
suppressor genes [81]. Inhibition of the PI3K/mTOR pathway or a
hypoxic environment leads to activation of autophagy [91] and may
also be of interest in EC. mTOR pathway is a master regulator of cellular
growth, proliferation, survival and metabolism and negatively regulates
autophagy in response to changes in oxygen level and energy status
[92].
6. Autophagy
Autophagy is an evolutionarily conserved process of eukaryotic cells
designed to serve as a survival mechanism in which cell components are
captured by intracellular membrane structures, degraded and recycled
[91]. Upon starvation, hypoxia, pathogen invasion and chemoradiation
autophagy is upregulated to maintain cellular homeostasis and to
provide energy [93]. Autophagy may be a protective mechanism in
the early phases of tumorigenesis requiring high levels of protein
synthesis for the tumor to grow rather than protein degradation [94].
As such, inhibition of autophagy could contribute to tumor growth
[94]. However, established tumors highjack autophagy to promote
survival in response to cellular stress during starvation, hypoxia and
therapy [94] and activate EMT, increasing invasiveness, metastatic
potential and CSCs [95] (Fig. 2).
For EC it was shown that chemotherapeutic resistant cells activated
autophagy which made them able to recover after therapy in contrast to
chemosensitive EC cells [96]. In addition, inhibition of autophagy in
resistant cell lines induced sensitization to chemotherapy [96] whereas
enhancing autophagy led to higher survival in EC [97,98]. Further-
more, whereas radiation can induce autophagy and promote cell
survival, combination of autophagy inhibitors with radiation enhances
its deleterious eﬀects on the tumor [99,100]. Interestingly, autophagy
related markers LC3II positively and p62 negatively correlated to poor
prognosis in EC patients [101–104]. Altogether, also autophagy seems
to contribute greatly to the gain of EC cancer stemness by increasing
drug resistance, invasiveness and the development of metastases, and
may oﬀer great potential for interference strategies.
7. The Cancer Genome Atlas (TCGA)
In the search for potential novel targets to eradicate highly
metastatic CSC populations in EC, data from the TCGA network can
be used. In the TCGA for gastroesophageal cancer, four subsets of
genetic alterations have been identiﬁed; Epstein-Barr virus (EBV)
related tumors with PIK3CA mutations/PD-L1/2 ampliﬁcations, micro-
satellite instability-high (MSI-H) tumors, genomic stable tumors (GS)
and tumors with chromosomal instability (CIN) [105].
Moreover, in the TCGA analyses, a pattern of multiple genetic
alterations has been detected with signiﬁcant diﬀerent molecular
changes between the two main histologic types of esophageal cancer
[106]. In EAC, ERBB2, VEGFA, GATA4 and GATA6 may be altered
more frequently than in ESCC [105,106]. Reversely, alterations in the
mTOR pathway genes PIK3CA/AKT and PTEN, TP63/SOX2 ampliﬁca-
tion and mutations in NOTCH1 are more frequently observed in ESCC
[105,106]. TCGA analyses may be used in EC CSC derived organoids in
both identiﬁcation and validation of potentially novel biomarkers.
Moreover, genome guided trials with stratiﬁcation based on patient
tumor derived CSC containing organoids using the TCGA distinct
subsets of genetic alterations seem promising and should be developed
in the near future.
8. Clinical perspectives
Although successful EC cancer therapy is measured mainly by the
level of downsizing the primary tumor and minimizing metastases
[107], CSCs may survive therapy and subsequently re-enter cell cycle.
Therefore, future therapies should consider CSCs. Due to the anecdotal
nature of the current knowledge, CSC markers have not been imple-
mented in EC for prognosis or to monitor disease progression. Interest-
ingly, enrichment of CSCs could result from current anti-cancer
therapies due to death of bulk tumor cells and the dediﬀerentiation
of EC cells e.g. activating EMT and autophagy [79,80,99,100]. Ded-
iﬀerentiation of non-CSCs to CSCs induced by tumor microenvironment
remains a huge challenge as it is not simply targeting a static population
[17]. Following this notion, future anti-cancer therapy should be based
on 1) eliminating the existing CSC population, by e.g. inhibitors of
aberrant activated signaling pathways and 2) prevent dediﬀerentiation,
hereby pushing the cancer cells into diﬀerentiation and making them
more susceptible to conventional chemoradiation. Patient’s speciﬁc
aberrant activation of e.g. HH, WNT, Notch pathways, hypoxia and
autophagy can be exploited to ﬁnd new personalized therapeutic




Although HH inhibitors are explored extensively in clinical trials for
diﬀerent solid tumors, clinical trials on EC are limited. Vismodegib, a
Ptch1 and SMO inhibitor regretfully did not show a survival beneﬁt in
gastroesophageal junction tumors in combination with chemotherapy
(FOLFOX) [108]. Currently, Vismodegib combined with nCRT is under
investigation in a clinical trial in HH activated EAC (www.NIH.com). In
our hands, Vismodegib did reduce the CSC pool in EC cell lines
(unpublished). Another SMO inhibitor, BMS-833923 combined with
chemotherapy is currently under investigation in inoperable metastatic
EC patients [109], whereas the use of SMO inhibitors sonidegib and
taladegib are being explored currently [109,110].
8.2. WNT, Notch and YAP1 inhibitors
A few WNT inhibitors, PRI-724, LGK-974, Vantictumab and OMP-
54F28 as a single agent or in combination with conventional therapy,
are currently in clinical trial in solid cancers [109]. Unfortunately, trials
on EC still need to be conducted [109]. The γ-secretase inhibitors,
R04929097, LY900009, PF-03084014, BMS-906024 and BMS-986115,
and MEDI0639 (anti-DLL4), OMP-59R5 (anti-Notch2/3), OMP-52M51
(anti-Notch1), Demcizumab (anti-DLL4) and Enoticumab (anti-DLL4)
all inhibiting Notch signaling have made it to clinical studies in solid
cancers [109]. Unfortunately, so far to our knowledge none of these
drugs have been used on EC yet [109]. YAP1, the major eﬀector target
of the Hippo pathway, can also be inhibited by the small molecule
Verteporﬁn. However, its signifance is yet to be validated in clinical
trials.
8.3. Hypoxia and autophagy
Smit and colleagues showed that CD44+/CD24− cells reside in
hypoxic niches of EC xenograft derived tumors [17]. Preliminary data
from our lab show increases in EC CSCs under low oxygen conditions,
indicating the need to target hypoxia to eradicate all tumor cells. There
are two main strategies targeting tumor hypoxia. The ﬁrst one is the
application of bioreductive prodrugs and the second approach is the use
of inhibitors of molecular targets upon which hypoxic cells depend on
[111]. A few prodrugs are currently in clinical trial such as Tirapaza-
mine, Apaziquone, TH-302, PR-104, Banoxantrone and RH1 in other
solid cancers and might provide new insights for targeting hypoxia in
EC [111]. The second involve two major pathways that are essential in
mediating tumor hypoxia, the HIF family of transcription factors and
the UPR pathway [111]. EZN-2968 and Topotecan are targeting HIF1α
while Geldanamycin is targeting the UPR pathway. mTOR inhibitors
such as Metformin, Rapamycin, Torin-1 can also be explored in
modulating tumor hypoxia [111]. Drugs targeting autophagy, down-
stream of mTOR, such as Baﬁlomycin and Chloroquine could also be
approached in EC [110].
9. Summary
Currently, several markers to describe EC CSCs have been suggested
and may be of prognostic or predictive value for response to therapy or
the development of metastases. These markers as well as certain
signaling pathways could be targeted in eliminating CSCs. However,
the great challenge is the tumor microenvironment rendering the
induction of potentially new CSC populations and needs further
exploration but certainly provides avenues for drug intervention.
Although EC has a poor prognosis, targeting patients speciﬁc CSC
cues may improve clinical outcome in the near future. As such, careful
analysis of patient’s speciﬁc tumor may lead to a personalized medicine
approach, where both CSC and the bulk tumor can potentially be
eradicated leading to a more satisfactory outcome for EC patients.
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